Articles tagged "Induction therapy"

2016 American Transplant Congress
Tailored Rabbit Anti-Thymocyte Globulin Induction (rATG) Dosing for Kidney Transplantation.
N. Singh,^1,2 A. Rossi,¹ M. Savic,¹ R. Rubocki,¹ M. Parker,¹ J. Vella.¹
¹MMC, Portland, ME; ²MGMC, Augusta, ME.
Purpose: Although rATG is the most commonly used induction immunotherapy for kidney transplantation (KT), optimal dosing remains unknown. In order to minimize adverse effects and…
2016 American Transplant Congress
Alemtuzumab Induction Therapy in Elderly Kidney Transplant Recipients.
I. Yakubu,¹ B. Masters,¹ B. Ravichandran,¹ T. Sparkes,¹ M. Moss,¹ F. Rasetto,¹ S. Jonchhe,¹ B. Thomas,² N. Costa,² D. Leeser,² S. Bartlett,² A. Haririan.²
¹Pharmacy, University of Maryland Medical Center, Baltimore; ²University of Maryland Medical Center, Baltimore.
Background: In descriptive studies, alemtuzumab has been associated with an escalating risk of death and graft loss in elderly (≥65 years) kidney transplant recipients. However,…
2016 American Transplant Congress
Time Trends of Induction Agent Use in Older and Younger Kidney Transplantation Recipients.
Q. Huang, X. Luo, M. McAdams-DeMarco, D. Segev.
Johns Hopkins University, Baltimore, MD.
Older adults are increasingly gaining access to kidney transplantation (KT) yet the use of induction agents in this population is unclear. The goal of this…
2016 American Transplant Congress
Tolerogenic Interactions Between Host CD8⁺Myeloid Dendritic Cells and Natural Killer T Cells Are Required for Acceptance of Combined Organ and Bone Marrow Transplants After TLI Conditioning.
D. Hongo Apum,¹ X. Zhang,² E. Engleman,² S. Strober.¹
¹Medicine - Division of Immunology & Rheumatology, Stanford University, Stanford, CA; ²Medicine - Department of Pathology, Stanford University, Stanford, CA.
Combined transplantation of solid organs and bone marrow or hematopoietic progenitor cells has resulted in successful achievement of tolerance in both laboratory animals and in…
2016 American Transplant Congress
After Alemtuzumab Induction, Tac+MMF Is Superior to CsA+MMF in Pediatric Kidney Transplantation.
M. Kaabak,¹ N. Babenko,¹ A. Zokoyev,¹ R. Shapiro.²
¹Boris Petrovsky SCS, Moscow, Russian Federation; ²Mount Sinai Hospital, New York, NY.
Introduction: Recipient parenchymal lymphatic cells are crucial for direct and indirect pathways of allorecognition. We proposed that administering alemtuzumab several weeks pretransplantation could eradicate peripheral…
2016 American Transplant Congress
A Prospective Randomized, Comparative Trial of High-Dose Mizoribine versus Mycophenolate Mofetil in Combination with Tacrolimus and Basiliximab for Living Donor Renal Transplantation: A Multi-Center Trial.
H. Ishida,¹ K. Tanabe,¹ S. Takahara,² N. Amada,³ K. Takahashi,⁴ H. Toma.⁵
¹Urology, Tokyo Women's Medical University Hospital, Tokyo, Japan; ²Advanced Technology for Transplantation, Osaka University, Osaka, Japan; ³Surgery, JCHO Sendai Hospital, Sendai, Japan; ⁴Niigata Organ Transplant Foundation, Niigata, Japan; ⁵Urology, Toda Chuo Hospital, Toda, Saitama, Japan.
PURPOSE: To compare the clinical outcomes of mizoribine (MZR; 12 mg/kg/day) and mycophenolate mofetil (MMF; 2000 mg/day) in combination with tacrolimus (FK), basiliximab (SIM), and…
2016 American Transplant Congress
Non-Human Primate Lung Allograft Survival Is Prolonged by IL-6 Inhibition and ATG Treatment Possibly Through Expansion of Peripheral Regulatory T Cells.
A. Aoyama, M. Tonsho, R.-N. Smith, R. Colvin, A. Dehnadi, J. Madsen, A. Cosimi, G. Benichou, T. Kawai, J. Allan.
Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA.
BACKGROUND: Inflammatory responses have been linked to the development of acute and chronic rejection after lung transplantation in various models. Previous studies have demonstrated that…
2016 American Transplant Congress
Outcomes in Elderly Renal Transplant Recipients Using Thymoglobulin or Interleukin-2 Receptor Antagonist Induction.
N. Jasiak,¹ J. Thielke,¹ J. Chen,² N. Hilal,¹ S. Salah,¹ D. Wu,¹ E. Benedetti,² P. West-Thielke.^1,2
¹Pharmacy, University of Illinois, Chicago; ²Transplant Surgery, University of Illinois, Chicago.
Background: Approximately 20% of all renal transplants performed in the US in 2014 occurred in elderly patients. Elderly patients are known to be at higher…
2016 American Transplant Congress
Implementation of a Risk Stratified Approach for Prevention of Hepatitis B Reactivation Post Kidney Transplant.
M. Cote,¹ M. Pavlakis,² J. Ethridge,¹ C. Currier,² M. Curry,² E. Khankin,² F. Cardarelli,² K. Richards,^1,2 C. Rogers.^1,2
¹Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston; ²Transplant Institute, Beth Israel Deaconess Medical Center, Boston.
A large percentage of patients with end stage renal disease are known to be Hepatitis B virus (HBV) positive. A 2015 consensus guideline on use…
2016 American Transplant Congress
The Effect of Donor Age on Acute Rejection Age – The Clinical Impact of Donor Immuno-Senescence in the Modern Immunosuppressive Era.
U. Khalid, P. Donato, L. Szabo, R. Chavez, E. Ablorsu, A. Asderakis.
Cardiff Transplant Unit, University Hospital of Wales, Cardiff, United Kingdom.
Experimental work has shown that donor age may alter the immune response of the recipient so that older donor grafts elicit a stronger response in…